Telegram Group & Telegram Channel
科济药业 Claudin18.2 CAR-T 拟纳入优先审评,针对胃癌

舒瑞基奥仑赛注射液(CT041)是科济药业开发的靶向Claudin18.2蛋白的自体CAR-T细胞产品,该蛋白在胃癌和胰腺癌中表达率超50%,适合治疗晚期胃/食管胃结合部腺癌。2020年9月,CT041获美国FDA孤儿药资格认定用于胃癌/食管胃结合部腺癌治疗。

媒体报道
科济药业-B现涨逾3% 子公司申报的舒瑞基奥仑赛注射液拟纳入优先审评 新浪科技
科济药业 Claudin18.2 CAR-T 拟纳入优先审评,针对胃癌 医药魔方
治疗胃癌,科济药业CAR-T细胞疗法拟纳入优先审评! 医药魔方
潜在首款!科济药业CAR-T疗法拟纳入优先审评 医药魔方

事件追踪
2025-02-26 科济药业引入珠海软银欣创投资以加速通用型CAR-T细胞产品在中国内地进程
2024-03-01 国内第五款,科济药业BCMA CAR-T疗法获批上市
2024-03-01 科济药业:CAR-T产品泽沃基奥仑赛注射液在中国获批上市

#热门话题



tg-me.com/readhub_cn/264230
Create:
Last Update:

科济药业 Claudin18.2 CAR-T 拟纳入优先审评,针对胃癌

舒瑞基奥仑赛注射液(CT041)是科济药业开发的靶向Claudin18.2蛋白的自体CAR-T细胞产品,该蛋白在胃癌和胰腺癌中表达率超50%,适合治疗晚期胃/食管胃结合部腺癌。2020年9月,CT041获美国FDA孤儿药资格认定用于胃癌/食管胃结合部腺癌治疗。

媒体报道
科济药业-B现涨逾3% 子公司申报的舒瑞基奥仑赛注射液拟纳入优先审评 新浪科技
科济药业 Claudin18.2 CAR-T 拟纳入优先审评,针对胃癌 医药魔方
治疗胃癌,科济药业CAR-T细胞疗法拟纳入优先审评! 医药魔方
潜在首款!科济药业CAR-T疗法拟纳入优先审评 医药魔方

事件追踪
2025-02-26 科济药业引入珠海软银欣创投资以加速通用型CAR-T细胞产品在中国内地进程
2024-03-01 国内第五款,科济药业BCMA CAR-T疗法获批上市
2024-03-01 科济药业:CAR-T产品泽沃基奥仑赛注射液在中国获批上市

#热门话题

BY Readhub


Warning: Undefined variable $i in /var/www/tg-me/post.php on line 283

Share with your friend now:
tg-me.com/readhub_cn/264230

View MORE
Open in Telegram


Readhub Telegram | DID YOU KNOW?

Date: |

Importantly, that investor viewpoint is not new. It cycles in when conditions are right (and vice versa). It also brings the ineffective warnings of an overpriced market with it.Looking toward a good 2022 stock market, there is no apparent reason to expect these issues to change.

The S&P 500 slumped 1.8% on Monday and Tuesday, thanks to China Evergrande, the Chinese property company that looks like it is ready to default on its more-than $300 billion in debt. Cries of the next Lehman Brothers—or maybe the next Silverado?—echoed through the canyons of Wall Street as investors prepared for the worst.

Readhub from us


Telegram Readhub
FROM USA